Today’s on-line publication by scientists working with BrainStorm Cell
Therapeutics Inc. (OTCBB:BCLI), demonstrates that human-derived adult
Stem Cells may be induced to...
PD
is a chronic, progressive neurodegenerative disorder that affects nerve
cells in the brain that produce dopamine, a chemical messenger
(neurotransmitter) that directs and controls...
Company Reports Preliminary Results from Safety Supporting Study in Primates
NEW
YORK & PETACH TIKVAH, Israel – August 14, 2007 – BrainStorm Cell
Therapeutics Inc. (OTCBB:...
BrainStorm Cell Therapeutics Inc. is an emerging company developing
neural-like stem cell therapeutic products, NurOwn(TM), based on
autologous bone marrow derived stromal cells, for treatment of...
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of
adult stem cell technologies and therapeutics, is pleased to announce
that the Company has...
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of
adult stem cell technologies and therapeutics, announces the
constructing of its new vivarium, an...
BrainStorm Adult Stem Cell Treatment should not Pose the Risk of
Teratomas (cancer) that Characterize Embryonic Stem Cell Therapies;
Company’s Adult Stem Cell Therapies...
ACCBT Corp. Invests Additional $750,000 in Leading Adult Stem Cell
Research Company
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of
...
NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- BrainStorm Cell Therapeutics
Inc. (OTC Bulletin Board: BCLI), a leading developer of adult stem cell
technologies and...
BrainStorm Conducts Positive Preliminary Meeting With Representatives
of CBER, FDA
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a developer of
autologous adult stem...
NEW YORK & PETACH TIKVA, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTCBB:BCLI), a leader in Adult Stem Cell Research, announced today that it has initiated a safety trial using...
#11: BCLI News BrainStorm Cell Therapeutics Enters Letter of Intent to Begin Preclinical Primate Studies of Stem Cell-Based Therapy for Parkinson's Disease; Testing to Begin by Year-End, With Clinical Human Trials to Follow As Soon As Possible
NEW YORK--(BUSINESS WIRE)--Sept. 12, 2006--BrainStorm Cell Therapeutics (OTCBB:BCLI), a leader in Adult Stem Cell Research, announced today that it has entered into a Letter Of Intent (LOI) with...
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Aug. 28, 2006--BrainStorm Cell Therapeutics (OTC BB: BCLI) is pleased to announce a well-respected firm, TRI-STATE Capital (TSC), has upgraded their...
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Aug. 24, 2006--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), the developer of NurOwn(TM) bone marrow-derived stem cell therapeutic products for the...
